OPEN

Data Descriptor: Genome-wide expression datasets of anti-VEGF and dexamethasone treatment of angiogenesis in the rat cornea

Received: 28 November 2016

Accepted: 27 February 2017

Published: 15 August 2017

Anthony Mukwaya¹, Pierfrancesco Mirabelli¹, Anton Lennikov¹, Maria Xeroudaki¹, Mira Schaupper¹, Beatrice Peebo¹ & Neil Lagali¹

Therapeutics against pathologic new blood vessel growth, particularly those targeting vascular endothelial growth factor (VEGF) are of enormous clinical interest. In the eye, where anti-VEGF agents are in widespread clinical use for treating retinal and corneal blindness, only partial or transient efficacy and resistance to anti-VEGF agents are among the major drawbacks. Conversely, corticosteroids have long been used in ophthalmology for their potency in suppressing inflammation and angiogenesis, but their broad biological activity can give rise to side effects such as glaucoma and cataract. To aid in the search for more targeted and effective anti-angiogenic therapies in the eye, we present here a dataset comparing gene expression changes in dexamethasone versus anti-*Vegf*a treatment of inflammation leading to angiogenesis in the rat cornea. Global gene expression analysis with GeneChip Rat 230 2.0 microarrays was conducted and the metadata submitted to Expression Omnibus repository. Here, we present a high-quality validated dataset enabling genome-wide comparison of genes differentially targeted by dexamethasone and anti-*Vegf* treatments, to identify potential alternative therapeutic targets for evaluation.

Design Type(s)	parallel group design • compound treatment design
Measurement Type(s)	transcription profiling assay
Technology Type(s)	microarray
Factor Type(s)	compound based treatment
Sample Characteristic(s)	Rattus norvegicus • cornea

¹Department of Ophthalmology, Institute for Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping 58183, Sweden. Correspondence and requests for materials should be addressed to N.L. (email: neil.lagali@liu.se).

Background & Summary

Pathological angiogenesis is a hallmark of many blinding diseases such as age-related macular degeneration, diabetic retinopathy, and corneal graft failure. In the eye, angiogenesis (or neovascularisation) is favoured by stimuli such as inflammation¹, immunologic rejection, limbal stem cell deficiency, and hypoxia². The choice of treatment for neovascularisation in the eye can be influenced by the stage of the neovascularisation process. While newly formed sprouts are usually leaky and susceptible to anti-VEGF treatment³, mature vessels require fewer angiogenic mediators⁴ necessitating other angioregressive therapies⁵. In the cornea in particular, therapeutics are used off-label to manage corneal angiogenesis, given the current lack of approved treatments specific for the cornea. Corticosteroids and/or nonsteroidal anti-inflammatory drugs (NSAIDs) are used to target neovascularisation^{6,7}, however, steroids may promote infection^{8,9}, glaucoma¹⁰, cataract¹¹, and herpes simplex recurrence^{12,13} while NSAIDs are reported to cause corneal ulceration and melting¹⁴.

To date, targeting the VEGF family of pro-angiogenic factors is the most promising therapeutic approach as an alternative to steroid or NSAID use. Bevacizumab, a full-length recombinant humanized monoclonal antibody against VEGFA has been reported to treat corneal neovascularisation with some success^{15,16}. Ranibizumab, a monoclonal antibody fragment also targeting VEGFA has similarly been shown to treat corneal neovascularisation¹⁷ and corneal graft rejection¹⁸. Compared to bevacizumab and ranibizumab, pegaptanib (a 28-base ribonucleic aptamer) is of limited efficacy, since it is specific to the VEGF-165 isoform¹⁹. The VEGF trap (aflibercept), a decoy receptor for all VEGFA isoforms, is the latest therapeutic approach being tested for use in the cornea²⁰. In spite of the benefits of these anti-VEGF targeted therapies, some side effects of VEGF targeting have been documented, for example impaired corneal epithelialization and wound healing, a pathology attributed to the possible adverse effects of VEGF deficiency on nerve growth and regeneration^{21,22}. In addition, anti-VEGF therapies are reported to be only partially effective^{23,24}. Likewise, an antisense oligonucleotide against the insulin receptor substrate-1, aganirsen, was recently reported to reduce corneal neovascularisation only partially (by 26%) in patients with keratitis in a phase III study¹⁹. In a previous study we reported that topical administration of anti-*Vegf* led to a 14% reduction in neovessels compared to a 90% reduction with dexamethasone treatment in a rat corneal model of angiogenesis²⁵.

In summary, there is need for new targeted therapies that mimic the potent effects of corticosteroids, but without the side effects attributed to their broad activity. A better understanding of specific factors suppressed by steroids but not by VEGF-A blockade is of potential importance for the development of more effective therapies. Here, we provide a detailed comparative dataset describing whole-genome differences in the activity of the corticosteroid dexamethasone, versus anti-VEGF treatment in a rat model of inflammatory corneal angiogenesis. GeneChip Rat 230 2.0 microarrays were used to monitor the global gene expression changes, and all microarray files including associated controls are described here, along with detailed information on the conditions of their generation and instructions for their re-use.

The dataset described here (Data Citation 1) can be a valuable resource for investigating genes and pathways to identify novel factors to target in order to improve the management of inflammation-associated neovascularisation in the cornea. The dataset described here has been thoroughly analysed in our related manuscript²⁶, where it was shown that dexamethasone treatment led to a suppression of inflammatory chemokines and other genes within known signaling pathways like PI3K-Akt and focal adhesion, while notably anti-*Vegf* treatment did not have this suppressive activity. Furthermore, dexamethasone treatment led to an unexpected activation of the classical complement pathway²⁶.

Methods

The methods described here are an expansion of those described in our related work²⁶.

Suture model of inflammatory corneal angiogenesis

The model of suture induced cornea neovascularisation was used as previously described^{1,25,27}. In summary, two nylon sutures were placed temporally to induce an inflammatory response that leads to new sprouting from limbal vessels after 2–3 days²⁷. As a follow up of our previous findings²⁵, here eye drops were administered topically immediately after suture placement i.e., during the pre-sprouting phase, but with high inflammation present in the cornea. At 48 h, *in vivo* confocal microscopy (IVCM) and slit lamp data was collected and corneal tissue was harvested for RNA processing. Global gene expression changes were assayed using microarrays. An illustration of the experimental design is shown in Fig. 1.

Treatment regime. Three groups of six rats each were treated with one of three topical treatments: IgG (Cat. No. 108-C, R&D Systems) at 20 $\mu\text{g ml}^{-1}$, anti-*Vegf* (Cat. No AF 564, a neutralizing rat-specific goat polyclonal pan-VEGFA antibody, R&D Systems, Minneapolis MN, USA) at 20 $\mu\text{g ml}^{-1}$ or dexamethasone (Opnol, Clean Chemical, Sweden AB, Borlänge, Sweden) at 1 mg ml^{-1} . The treatments were administered topically, 4 times daily, starting immediately following suture placement, and continuing up to 48 h (Fig. 1). Additionally, a group of four non-sutured and non-treated corneas was harvested to serve as the control.

Figure 1. Schematic illustration of the experimental procedure that was followed. (1) sutures were placed intrastromally into the temporal cornea, and immediately followed by topical application of eye drops (IgG, anti-*Vegf* or dexamethasone). Eye drops were applied until the 48 h time point. At $t=48$ h, IVCM and slit lamp data was collected and used for phenotypic characterisation. (2) cornea tissue was harvested and used for RNA extraction, and RNA quality verified. (3) high quality RNA was used for target preparation for microarray hybridisation on to GeneChip Rat 230 2.0 microarray chips. The microarray chips were scanned and image files acquired. (4) CEL files were normalised using expression console software. The generated CHP together with the CEL files were submitted to Gene Expression Omnibus repository.

Sample collection and RNA extraction. After 48 h of topical treatment, animals were euthanized and a standardized region of tissue between the sutures and limbus which indicated a strong inflammatory response by *in vivo* confocal microscopy²⁶ was carefully dissected out. The tissue was harvested from all groups (i.e., IgG, anti-*Vegf*, dexamethasone and non-sutured/non-treated control), six animals per treatment group and then immediately immersed in RNA later (Qiagen) and temporarily stored at 4 °C. Total RNA was then extracted from all the six samples using Qiagen mini RNA preparation kit (Qiagen). RNA concentration was then determined using a NanoDrop spectrophotometer (Thermo Scientific), and RNA quality was determined using the Agilent bioanalyzer 2100 (Agilent Technologies). RNA integrity number (RIN) ≥ 7 was set as the cut-off for sample inclusion for downstream processing for microarray analysis. Of the six RNA samples extracted per treatment group, four RNA samples per treatment group (with highest RIN) were selected for downstream processing.

Microarray target preparation. GeneChip Rat 230 2.0 microarrays were used for global gene expression analysis. Four microarray chips were used per experimental group, including non-sutured and non-treated control corneas. Each microarray chip represented a single corneal sample (16 microarrays in total) i.e., no pooling of cornea tissue was performed. As per the protocol (Manual Target Preparation for GeneChip 3' Expression Arrays-Affymetrix), a total of 100 ng of high quality RNA per sample was mixed with poly-A spike-in Controls, and the mixture was used for first-strand synthesis to yield single-stranded cDNA with the T7 promoter sequence at the 5' end. Next, using a DNA polymerase and RNase H, the single-stranded cDNA was converted to double-stranded cDNA to serve as a template for *in vitro* transcription using T7 RNA polymerase. This resulted in the synthesis of labelled complementary RNA (cRNA). The labelled cRNA was then purified, and then

GSM-ID	ID	Organism	Age (Weeks)	Description/ Treatment	Sample type and source	Technology
GSM2327895	F1	rattus norvegicus albino	12	anti-Vegf_F1	RNA-Cornea	Microarray
GSM2327896	F2	rattus norvegicus albino	13	anti-Vegf_F2	RNA-Cornea	Microarray
GSM2327897	F6	rattus norvegicus albino	12	anti-Vegf_F6	RNA-Cornea	Microarray
GSM2327898	F7	rattus norvegicus albino	13	anti-Vegf_F7	RNA-Cornea	Microarray
GSM2327899	F17	rattus norvegicus albino	12	IgG_F17	RNA-Cornea	Microarray
GSM2327900	F19	rattus norvegicus albino	13	IgG_F19	RNA-Cornea	Microarray
GSM2327901	F22	rattus norvegicus albino	13	IgG_F22	RNA-Cornea	Microarray
GSM2327902	F23	rattus norvegicus albino	12	IgG_F23	RNA-Cornea	Microarray
GSM2327903	F25	rattus norvegicus albino	13	dexamethasone_F25	RNA-Cornea	Microarray
GSM2327904	F26	rattus norvegicus albino	13	dexamethasone_F26	RNA-Cornea	Microarray
GSM2327905	F27	rattus norvegicus albino	12	dexamethasone_F27	RNA-Cornea	Microarray
GSM2327906	F30	rattus norvegicus albino	12	dexamethasone_F30	RNA-Cornea	Microarray
GSM2327907	Cont 1	rattus norvegicus albino	13	Control 1	RNA-Cornea	Microarray
GSM2327908	Cont 2	rattus norvegicus albino	13	Control 2	RNA-Cornea	Microarray
GSM2327909	Cont 3	rattus norvegicus albino	12	Control 3	RNA-Cornea	Microarray
GSM2327910	Cont 4	rattus norvegicus albino	12	Control 4	RNA-Cornea	Microarray

Table 1. Dataset and sample description across treatment groups.

Figure 2. RNA and microarray data quality check. Following Bioanalyser RNA quality check, (a) is an electrophoregram showing RNA sample quality. The distinct peaks in (a) represent the 18 and 28 s rRNA. (b) are the obtained RIN values across treatments. (c) is a display of the Relative Log Expression Signal-RMA, while (d) are Boxplot of four of Affymetrix Spike-In controls, lys-M, phe-M, thr-M and dap-M illustrating the range of signal (log2) over the experiment as well as quality control of the arrays technical run. (e) is the PCA-Probe Cell Intensity Data.

Figure 3. A correlation analysis within treatment group. (a–d) are signal intensity values correlated between control, IgG, anti-*Vegf* and dexamethasone treated samples respectively. (e) is an example of pathway enrichment analysis and (f) is a display of the genes involved in a selected pathway (PI3K-Akt signalling pathway).

both the yield and size distribution was verified using a NanoDrop spectrophotometer. The labelled cRNA was then fragmented and used for the preparation of the array hybridisation master mix. Samples were hybridised to the microarray chips at 60 rpm for 16 h, at 45 °C in GeneChip Hybridization Oven 645 (Affymetrix, Inc.). The microarray chips were washed and stained in a GeneChip Fluidics Station 450 (Affymetrix, Inc.) and then scanned in a GeneChip Scanner 3000 7 G (Affymetrix, Inc.).

Data Records

Following data acquisition, the CEL files were normalised, and CHP files were generated using Expression Console Software (Affymetrix, Inc.). The CEL and CHP files were submitted to Gene Expression Omnibus repository (Data Citation 1). The samples used in the study are summarised in Table 1.

Technical Validation

Following suture placement, randomisation was performed in assigning the rats to different treatment groups. For the purpose of statistical inference, a total of four rats was used per treatment to correspond

Figure 4. Gene fold change, and localisation of target protein expression in cornea sections. (a) is the gene fold change by microarray. (b) is the gene fold change by qPCR. $n=4$ and 3 corneas for (a,b), respectively. ANOVA followed by Tukey's multiple comparisons test was used to isolate pairwise differences, with $\alpha < 0.05$. In both (a,b), asterisks represent adjusted $P < 0.05$ and the error bars represent standard deviation. ns, not significant. The data in (a,b) was analysed using GraphPad Prism 5 (GraphPad Software, Inc. CA 92037 USA). (c) is the localisation of the corresponding protein expression in cornea cross sections stained by immunohistochemistry. White scale bars represent 20 μ m.

to four microarray chips per treatment group. ANOVA was used to compare effects of the given treatments across treatment groups, with Tukey multiple comparison test used to isolate pairwise differences.

Efficacy of the anti-Vegf treatment was verified by Western blot analysis prior to the beginning of the study to confirm the expected effect on the gene target²⁶. Suture placement was performed by the same experienced surgeon for all treatment groups, to reduce the chances of technical variation. In addition, a similar phenotypic appearance within each group was confirmed by slit lamp biomicroscopy and *in vivo* confocal microscopy²⁶.

RNA quality check

The quality of the RNA was checked prior to downstream analysis, using the Agilent Bioanalyser 2100 (Agilent Technologies), using the 2100 expert_Eukaryote Total RNA Nano settings. The analysis showed clear, defined 28 and 18 s rRNA peaks, an indication of high quality RNA. Moreover, low noise between the peaks, and minimal low molecular weight noise was detected. In Fig. 2a an electrophoregram is presented illustrating the peaks for the 18 and 28 s rRNA, and in Fig. 2b the sample RIN values are given.

Quality control of microarray data

The raw CEL files were converted into expression measures, background-corrected, and data-normalized using the RMA method²⁸, with the help of Expression Console Software (Affymetrix, Inc). In Fig. 2c the relative log expression Signal-RMA is given. In Fig. 2d are boxplots representing four of the Affymetrix Spike-In controls, lys-M, phe-M, thr-M and dap-M illustrating the range of signal (log2) over the experiment. In Fig. 2e is the PCA-Probe Cell Intensity Data. The PCA1 (67.0%) represents anti-*Vegf* and IgG treated groups in blue and red colours, respectively. PCA2 (11.7%) represents dexamethasone treated group in the orange colour, while PCA3 (4.2%) displays the control samples in green colour. Note the partial overlap of anti-*Vegf* and IgG groups and clear separation from the dexamethasone treated corneas.

The CHP files were used for gene expression analysis using Transcriptome Analysis Console (TAC) Software (Affymetrix, Inc.). Using the obtained linearized signal intensity values from the TAC analysis, a correlation analysis between samples within the same treatment groups was performed. The resulting scatter plots with their corresponding correlation coefficient (R^2) are presented in Fig. 3a–d. There was strong correlation within samples of the same treatment group. The linearized values can then be log transformed and used for functional annotation analysis. As an example, STRING²⁹ pathway enrichment analysis was performed using the differentially expressed genes in the dexamethasone treated group. Selected pathways from this analysis are presented in Fig. 3e, and the genes involved in one of the pathways (PI3K-Akt signalling pathway) are represented as an example in Fig. 3f.

Gene fold change by qPCR

To validate microarray³⁰ gene fold change (Fig. 4a), here we used a separate set of rats (3 per treatment group) for qPCR analysis. Rats were sutured and treated identically as for microarray samples. At the 48 h time point, animals were sacrificed and cornea tissue was harvested and used for RNA extraction, without pooling. Following RNA extraction, cDNA was synthesised using superscript cDNA synthesis kit (Invitrogen), and used for qPCR analysis using TaqMan primers. Genes *Fgf7* and *Serpinb2* were assayed as exemplary genes, with results shown in Fig. 4b.

Localisation of translated genes

Cornea samples from the respective treatment groups were harvested and fixed in paraformaldehyde for 24 h, and then stabilised in paraffin blocks. Then 5 µm cross-sections of the tissue were made. Prior to staining, the sections were deparaffinised and rehydrated. The sections were probed with primary antibody for *Fgf7* and *Serpinb2*, and detected with fluorescently (Alexa 488) labelled secondary antibody Fig. 4c. Images were acquired using a laser scanning confocal fluorescent microscope (Zeiss LSM700).

Usage Notes

The raw CEL files can be normalised using Expression console, and gene fold change can be obtained using Transcriptome Analysis Console. Both software packages can be freely accessed from Affymetrix (Affymetrix Inc).

Transcriptome Analysis Console (Affymetrix Inc) can be used for pathway enrichment analysis, where both pathway *P*-value and significance can be obtained. The genes involved in a given pathway can also be mapped within a pathway of interest.

Also using other publicly available software for bioinformatics analysis such as STRING²⁹, Venny³¹, DAVID³², PANTHER³³, etc., and those commercially available like Ingenuity pathway analysis (IPA-Qiagen) (<http://www.ingenuity.com/>), the differentially expressed genes can be used to deduce pathway and biological processes of interest, and to further isolate the genes involved in them.

In combination with our recently published Data Descriptor³⁴, genes important for endogenous restoration of corneal avascularity during either an angiogenic sprouting or regression phase can be compared to their behaviour observed with either dexamethasone or anti-*Vegf* treatment in the current dataset, to gain an understating of how these treatments modulate these factors.

References

1. Mukwaya, A. *et al.* Factors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesis. *Scientific reports* **6**, 32137 (2016).
2. Hsueh, Y.-J., Chen, H.-C., Lai, J.-Y., Chen, J.-K. & Ma, D. H.-K. Corneal Neovascularization as a Target for Nucleotide-Based Therapies. *Journal of Clinical & Experimental Ophthalmology* **6**, 409 (2015).
3. Korn, C. & Augustin, H. G. Mechanisms of vessel pruning and regression. *Developmental cell* **34**, 5–17 (2015).
4. Lin, C.-T. *et al.* The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. *Investigative ophthalmology & visual science* **51**, 6277–6285 (2010).

5. Cursiefen, C., Hofmann-Rummelt, C., Kuchle, M. & Schlötzer-Schrehardt, U. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. *British journal of ophthalmology* **87**, 101–106 (2003).
6. Giannini, E. H. *et al.* Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. *New England Journal of Medicine* **326**, 1043–1049 (1992).
7. Cursiefen, C. *et al.* Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. *Graefes archive for clinical and experimental ophthalmology* **239**, 514–521 (2001).
8. Klotz, S. A., Penn, C. C., Negvesky, G. J. & Butrus, S. I. Fungal and parasitic infections of the eye. *Clinical microbiology reviews* **13**, 662–685 (2000).
9. Peponis, V., Herz, J. & Kaufman, H. The role of corticosteroids in fungal keratitis: a different view. *British journal of ophthalmology* **88**, 1227–1227 (2004).
10. Kersey, J. & Broadway, D. Corticosteroid-induced glaucoma: a review of the literature. *Eye* **20**, 407–416 (2006).
11. Jobling, A. I. & Augusteyn, R. C. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. *Clinical and experimental optometry* **85**, 61–75 (2002).
12. Smith, E. B. & Powell, R. F. Corticosteroids in herpes simplex and zoster. *International journal of dermatology* **14**, 341–345 (1975).
13. Lizarraga, K. J., Alexandre, L. C., Ramos-Estebanez, C. & Merenda, A. Are steroids a beneficial adjunctive therapy in the immunosuppressed patient with herpes simplex virus encephalitis? *Case reports in neurology* **5**, 52–55 (2013).
14. Flach, A. J. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. *Transactions of the American Ophthalmological Society* **99**, 205 (2001).
15. Manzano, R. P. *et al.* Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). *British journal of ophthalmology* **91**, 804–807 (2007).
16. Krizova, D., Vokrojova, M., Liehneova, K. & Studeny, P. Treatment of corneal neovascularization using anti-VEGF Bevacizumab. *Journal of ophthalmology* **4**, 178132 (2014).
17. Hurmeric, V. *et al.* Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium. *Clinical ophthalmology (Auckland, NZ)* **7**, 467 (2013).
18. Cho, K. J., Choi, J.-S., Choi, M. Y. & Joo, C.-K. Effects of subconjunctival ranibizumab in a presensitized rat model of corneal graft. *Experimental eye research* **107**, 74–79 (2013).
19. Ng, E. W. *et al.* Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. *Nature reviews drug discovery* **5**, 123–132 (2006).
20. Dohlman, T. H. *et al.* VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation. *Transplantation* **99**, 678–686 (2015).
21. Charles, Q. Y., Zhang, M., Matis, K. I., Kim, C. & Rosenblatt, M. I. Vascular endothelial growth factor mediates corneal nerve repair. *Investigative ophthalmology & visual science* **49**, 3870–3878 (2008).
22. Bock, F. *et al.* Safety profile of topical VEGF neutralization at the cornea. *Investigative ophthalmology & visual science* **50**, 2095–2102 (2009).
23. Lu, K. V. & Bergers, G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. *CNS Oncol* **2**, 49–65 (2012).
24. Loges, S., Schmidt, T. & Carmeliet, P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. *Genes & cancer* **1**, 12–25 (2010).
25. Mirabelli, P., Peebo, B. B., Xeroudaki, M., Koulikovska, M. & Lagali, N. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. *Experimental eye research* **125**, 118–127 (2014).
26. Mirabelli, P. *et al.* Genome-wide expression differences in anti-Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea. *Scientific Reports* **7** doi: 10.1038/s41598-017-07129-4, 16–44635 (2017).
27. Peebo, B. B., Fagerholm, P., Traneus-Röckert, C. & Lagali, N. Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model. *Angiogenesis* **14**, 393–405 (2011).
28. Irizarry, R. A. *et al.* Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* **4**, 249–264 (2003).
29. Szklarczyk, D. *et al.* STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic acids research* **43**, D447–D452 (2015).
30. Morey, J. S., Ryan, J. C. & Van Dolah, F. M. Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. *Biol. Proced. Online* **8**, 175–193 (2006).
31. Oliveros, J. C. An interactive tool for comparing lists with Venn Diagrams. *VENNY* <http://bioinfogp.cnb.csic.es/tools/venny/index.html> (2007–2015).
32. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature protocols* **4**, 44–57 (2009).
33. Mi, H., Poudel, S., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. PANTHER version 10: expanded protein families and functions, and analysis tools. *Nucleic acids research* **44**, D336–D342 (2016).
34. Mukwaya, A. *et al.* A microarray whole-genome gene expression dataset in a rat model of inflammatory corneal angiogenesis. *Sci Data* **3**, 160103 (2016).

Data Citation

1. Mukwaya, A. *et al.* *Gene Expression Omnibus* GSE87330 (2017).

Acknowledgements

The authors wish to acknowledge the technical support offered by Åsa Schippert and Annette Molbaek at the Linköping University core facility laboratory during the wet lab procedures. This study was supported in part by funding from the Swedish Research Council (Grant No. 2012- 2472). This work was also supported in part by a Research grant from the Swedish Ophthalmological Society Stiftelsen Synfrämjandets Forskningsfond/Ögonfonden. The authors also acknowledge the kind contribution of bioinformatics expertise and training by Jessica Lindvall, in the framework of the BILS (Bioinformatics Infrastructure for Life Sciences) program in Sweden.

Author Contributions

A.M., F.M., B.P. and N.L. developed the concept of the study. F.M., B.P., M.X. and N.L. designed the experiments. F.M., A.M., M.X., B.P., A.L., M.S. and N.L. performed *in vivo* experiments. A.M. processed

the microarrays and performed data quality control and data normalisation. A.M. and N.L. wrote the manuscript and all authors reviewed and approved the final manuscript.

Additional Information

Competing interests: The authors declare no competing financial interests.

How to cite this article: Mukwaya, A. *et al.* Genome-wide expression datasets of anti-VEGF and dexamethasone treatment of angiogenesis in the rat cornea. *Sci. Data* 4:170111 doi: 10.1038/sdata.2017.111 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

The Creative Commons Public Domain Dedication waiver <http://creativecommons.org/publicdomain/zero/1.0/> applies to the metadata files made available in this article.

© The Author(s) 2017